bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Oh a sale milestone with a 2027 expiration

Please read the SEC documents regarding this current security and understand that I do own of these shares. This isn’t an offer or solicitation to buy shares.

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone EXPIRES 2027

https://www.carlyle.com/media-room/news-release-archive/bluebird-bio-announces-definitive-agreement-be-acquired-carlyle-and

Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird’s current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027, for a potential total value of up to $9.84 per share in cash, subject to the tender of a majority of the outstanding shares of bluebird, receipt of applicable regulatory approvals, and other customary closing conditions. bluebird's Board of Directors (the “bluebird Board”) unanimously approved the agreement and recommends that stockholders tender their shares. Following a comprehensive review of bluebird’s strategic alternatives, including meeting with more than 70 potential investors and partners over a period of five months, and a third and final denial by the Federal Drug Administration of bluebird’s appeal for a priority review voucher, the bluebird Board determined that, absent a significant infusion of capital, bluebird is at risk of defaulting on its loan covenants. The bluebird Board has decided that this transaction is the only viable solution to generate value for stockholders. Additional details on the process will be available in bluebird’s Solicitation/Recommendation Statement on Schedule 14D-9, which will be filed with the U.S. Securities and Exchange Commission (“SEC”).

All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital.